/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR
DISSEMINATION IN THE UNITED STATES/
Other study shows GARDASIL(R) significantly reduced
abnormal Pap tests and follow-up procedures
MONTREAL, May 8 /CNW Telbec/ - The monovalent human papillomavirus (HPV)
type 16 L1 virus-like particle (VLP) vaccine demonstrated efficacy against
HPV-16 infection for an average of 8.5 years in a Phase II extension follow-up
study, according to data presented at the 25th Annual International
Papillomavirus Conference in Malmo, Sweden. The monovalent vaccine is a
component of GARDASIL(R) (Quadrivalent Human Papillomavirus (Types 6, 11, 16,
18) Recombinant Vaccine).
In another study in women who were naive to 14 common HPV types,
GARDASIL(R) reduced the number of abnormal Pap test results by 17 to 45 per
cent, depending on the abnormality, and reduced colposcopies by 20 per cent,
cervical biopsies by 22 per cent as well as surgery and other invasive
treatments by 42 per cent.
Be on the lookout for the b-roll to be distributed via satellite today
between 12:00 and 1:00 pm EDT. Coordinates: Anik F2C, Transponder 3B, D/L
Frequency 3820 vertical, Audio 6.2/6.8.
The news release is available at www.cnw.ca.
Content of footage will include:
- Interviews with medical/scientific experts
- Young women being vaccinated
- Woman undergoing a Pap test
- GARDASIL(R) manufacturing and packaging
For further information:
For further information: Montreal: NATIONAL Public Relations: Roch
Landriault, (514) 843-2345; Claude Arsenault, (514) 843-2388; Toronto:
NATIONAL Public Relations: Lynn Bessoudo, (416) 848-1426; Naziah Lasi, (416)